MXCT
MaxCyte, Inc.
$0.84
-3.24%
2026-05-08
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Key Fundamentals
Forward P/E
-3.16
EPS (TTM)
$-0.42
ROE
-23.6%
Revenue Growth (YoY)
-16.0%
Profit Margin
-135.1%
Debt/Equity
10.46
Price/Book
0.53
Beta
1.57
Market Cap
$90.5M
Avg Volume (10D)
465K
Recent Breakout Signals
No recent breakout signals detected for MXCT.
Recent Price Range (60 Days)
60D High
$0.90
60D Low
$0.64
Avg Volume
895K
Latest Close
$0.84
Get breakout alerts for MXCT
Sign up for Breakout Scanner to receive daily notifications when MXCT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
MaxCyte, Inc. (MXCT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MXCT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MXCT operates in the Healthcare sector within the Medical Devices industry. Data is provided for informational purposes only and does not constitute financial advice.